05.23.25 -- 8 Ways To Drive Resilience In Oncology Drug Supply Chains

Explore the critical aspects of GMP-grade raw materials in CGT manufacturing, including contamination control, aseptic strategies, quality systems, supply chain security, and regulatory compliance.

Drug manufacturers seek packaging that maintains integrity during processing and freezing, scales up to larger volumes easily, and remains robust throughout the temperature-controlled supply chain.

To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.

Maintaining drug product sterility and compliance demands rigorous Container Closure Integrity (CCI) within contract manufacturing. Learn how to fortify your processes.

Review the dynamic field of therapeutic biotechnology, the intricacies of mAb manufacturing, and the often-overlooked factors driving high production costs.

This article examines how micropositioners affect movement and positioning capability, as well as overall task effectiveness, by creating — literally — a solid foundation for work at the nanoscale.

Drug design using CRISPR depends on long guide RNA (gRNA) sequences. Find out how this match between long oligos and CRISPR works.

Uncover examples of visible particle identification and the root cause investigation, along with a discussion of the performance of additional troubleshooting using advanced and innovative technologies.

Navigating trials for viral vector-based C&G therapies demands specialized expertise and regulatory insight. Learn how scientific acumen and strategic planning bring therapies from lab to patient.

Optimizing recombinant expression and scalable purification strategies can help accelerate the production of challenging proteins, enabling successful program initiation and advancing pipelines.

Some membranes attract water ("hydrophilic"), while others repel it ("hydrophobic"). Here, we take a look at which is best for your application.

Delve into the key obstacles encountered in biologics process development, including the complexities of optimizing production processes, ensuring product consistency, and maintaining quality control.

Address analytical considerations and material flows that better facilitate the rapid delivery of toxicological material with these key strategies and technologies.

Enable the next generation of stable, scalable, and clinically advanced ADCs through site-specific conjugation with Abzena’s ThioBridge technology.